• Japanese
  • Korean
  • Chinese
Cover Image

High-Growth Diagnostic Testing Markets

There will be a steady increase in demand for new diagnostic testing services in the next five-year period, along with pressures to improve the quality of healthcare delivered in the clinic and also to lower its costs. Clinical labs experienced a substantial growth during the last decade. The emphasis in this TriMark Publications report is on those companies that are actively developing and marketing high-growth diagnostic testing technologies in the clinical hospital market. It defines the dollar volume of sales, both worldwide and in the U.S., of the market and analyzes the factors that influence the size and growth of market segments. The study goes on to discuss in detail trends that have developed which have stimulated this market, and also comments in detail patterns of information processing in the high-growth diagnostic testing technologies. Moreover, this exanimation provides an overview of the diagnostic testing market, including the latest information regarding exciting new products and industry trends. It will not only quantify but also qualify the market high-growth segments as an area of research and investment. Forecasts of the market and analyses of products in the worldwide prescriptions market will provide a basis for understanding the significance of past developments and future possibilities within this therapeutic category.

Table of Contents

1. Overview

  • 1.1. Statement of Report
  • 1.2. Scope of This Report
  • 1.3. Methodology
  • 1.4. Executive Summary

2. Introduction to the High-Growth Testing Market

  • 2.1. Introduction to the Global Diagnostic Market
  • 2.2. General Areas with Potential for High-Growth Testing
  • 2.3. Market Drivers in the High-Growth Diagnostics Testing Sector
  • 2.4. Market Segments for High-Growth Testing
  • 2.5. Key Players in the High-Growth Diagnostics Testing Segment
  • 2.6. High-Growth Testing Sector Analysis

3. Hepatitis Serologic Markers and Nucleic Acid Testing

  • 3.1. Hepatitis B Virus (HBV)
  • 3.2. Major Suppliers of Hepatitis B Virus (HBV) Testing Products
  • 3.3. Market Revenue Analysis
  • 3.4. Hepatitis C Virus (HCV) Testing
  • 3.5. Market Revenue Analysis
  • 3.6. Market Share Analysis

4. Human Papillomavirus (HPV) Testing

  • 4.1. Overview
  • 4.2. The Association of HPV and Cervical Cancer
  • 4.3. The PAP Test
  • 4.4. Current Laboratory Methods for HPV Detection
    • 4.4.1. Direct-Probe Methods
    • 4.4.2. Signal Amplification
    • 4.4.3. Target Amplification
  • 4.5. Assays for HPV
  • 4.6. Market Revenue Analysis
  • 4.7. Competitor Activity
  • 4.8. Market and Technology Trends
    • 4.8.1. Market Trends
    • 4.8.2. Technology Trends

5. HIV

  • 5.1. Introduction to HIV/AIDS
  • 5.2. Statistical Data Global HIV/AIDS Epidemic
  • 5.3. HIV Prevention and Treatment
    • 5.3.1. HIV Prevention
    • 5.3.2. HIV Treatment
  • 5.4. U.S. Testing Market
  • 5.5. Market Dynamics
    • 5.5.1. Market Drivers
    • 5.5.2. Market Restraints
    • 5.5.3. Market Trends
    • 5.5.4. Technology Trends
  • 5.6. Review of Selected HIV Testing Devices
  • 5.7. Market Revenue Analysis
  • 5.8. Competitor Activity
  • 5.9. HIV Market Challenges and Strategic Recommendations
  • 5.10. Insurance Coverage and Reimbursement
  • 5.11. Policies Affecting HIV Testing
  • 5.12. Recent Industry Activity

6. Infectious Disease Testing

  • 6.1. Introduction to Infectious Disease Testing
  • 6.2. Types of Diagnosis for Infectious Diseases
    • 6.2.1. Microbial Culture
    • 6.2.2. Microscopy
    • 6.2.3. Biochemical Tests
    • 6.2.4. Molecular Diagnostics
  • 6.3. Diagnostic Platforms for Infectious Diseases
    • 6.3.1. Centralized Laboratory Testing for Infectious Diseases
    • 6.3.2. POC Testing for Infectious Diseases
  • 6.4. Emerging Technologies
  • 6.5. Qualitative Analysis
    • 6.5.1. Market Drivers
    • 6.5.2. Market Restraints
  • 6.6. Streptococcus Testing
  • 6.7. Chlamydia Testing
  • 6.8. Mononucleosis
  • 6.9. Gonorrhea
  • 6.10. Influenza
  • 6.11. Malaria
  • 6.12. Tuberculosis
  • 6.13. Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • 6.14. Market Revenue Analysis

7. Cardiac Markers

  • 7.1. Market Overview
  • 7.2. Cardiac Marker Tests
    • 7.2.1. Creatine Kinase (CK)
    • 7.2.2. Myoglobin
    • 7.2.3. Cardiac Troponins T (TnT), I (TnI) and C (TnC)
    • 7.2.4. C-Reactive Protein (CRP)
    • 7.2.5. Homocysteine
  • 7.3. Emerging Markers
    • 7.3.1. B-type Natriuretic Peptide (BNP)
    • 7.3.2. Myeloperoxidase (MPO)
    • 7.3.3. Ischemia Modified Albumin (IMA)
    • 7.3.4. Glycogen Phosphorylase Isoenzyme BB (GPBB)
    • 7.3.5. Fatty Acid-Binding Proteins (FABPs)
  • 7.4. Qualitative Analysis
    • 7.4.1. Market Drivers
    • 7.4.2. Market Restraints
  • 7.5. Specific Cardiac Conditions
    • 7.5.1. Acute Myocardial Infarction
    • 7.5.2. Heart Failure (BNP)
      • 7.5.2.1. Market Overview
      • 7.5.2.2. Commercial Assays for BNP and NT-proBNP
      • 7.5.2.3. Clinical Applications of BNP
    • 7.5.3. CRP
  • 7.6. Pulmonary Embolism (D-dimer Test)
  • 7.7. Key Players
  • 7.8. Market Revenue Analysis

8. Cytogenetic Testing

  • 8.1. Cancer Testing
  • 8.2. Prenatal Testing and Cytogenetics
    • 8.2.1. Cystic Fibrosis Testing
      • 8.2.1.1. CF Testing Methodology
      • 8.2.1.2. CF Screening Technology Summary
  • 8.3. Key Players in Segment

9. Fertility Testing

10. Cancer Biomarker Testing

  • 10.1. Segment Overview
  • 10.2. The Cancer Testing Market
  • 10.3. Competition
  • 10.4. Individual Markets
    • 10.4.1. Cancer Pathology: Testing
      • 10.4.1.1. Rare Cell/Micro Metastasis Detection
      • 10.4.1.2. Cancer Pathology: High-Throughput Screening
      • 10.4.1.3. Competition
      • 10.4.1.4. Drivers
    • 10.4.2. Breast Cancer
      • 10.4.2.1. CA 15-3
      • 10.4.2.2. CA 27-29
      • 10.4.2.3. BRCA1 and BRCA2 Breast and Ovarian Cancer Genes
      • 10.4.2.4. Estrogen and Progesterone Receptor (ER and PR)
      • 10.4.2.5. Human Epidermal Growth Factor Receptor 2 (HER-2)
      • 10.4.2.6. Herceptin
      • 10.4.2.7. p53
      • 10.4.2.8. Nuclear Matrix Protein 66 (NMP66)
      • 10.4.2.9. Mammastatin
      • 10.4.2.10. Drivers for Breast Cancer Test Development
    • 10.4.3. Ovarian Cancer
      • 10.4.3.1. Cancer Antigen 125 (CA 125)
      • 10.4.3.2. BRCA1 and BRCA2
      • 10.4.3.3. Steroid Hormone Receptors
      • 10.4.3.4. Epidermal Growth Factor Receptor (EGFR)
      • 10.4.3.5. Lysophospholipids
    • 10.4.4. Cervical Cancer
      • 10.4.4.1. Cervical Cancer Screening Tests
    • 10.4.5. Colon Cancer DNA Testing
  • 10.5. Pharmacogenomic Cancer Testing
  • 10.6. Market Revenue Analysis

11. Substance Abuse Testing

  • 11.1. Background to POC Substance Abuse Testing
  • 11.2. Substance Abuse Test Types
    • 11.2.1. Urine Substance/Drug Screening
    • 11.2.2. Hair Tests for Substance Abuse and Screening
    • 11.2.3. Blood Tests for Substance Abuse and Screening
    • 11.2.4. Saliva Tests for Substance Abuse and Screening
    • 11.2.5. Sweat Tests for Substance Abuse and Screening
  • 11.3. Alcohol Abuse and Screening
  • 11.4. Saliva Testing
  • 11.5. Qualitative Analysis
    • 11.5.1. Market Drivers
    • 11.5.2. Market Restraints
  • 11.6. Review of Selected POC Substance Abuse Analyzers
  • 11.7. Review of Company Products
    • 11.7.1. Alere
    • 11.7.2. Abbott Diagnostics
    • 11.7.3. Roche Diagnostics
    • 11.7.4. BioScan Screening Systems, Inc.
    • 11.7.5. American Bio Medica Corp.
    • 11.7.6. Phamatech, Inc.
    • 11.7.7. First Check Medical
    • 11.7.8. OraSure
    • 11.7.9. Avitar, Inc.
    • 11.7.10. Concateno (Alere, Inc.)
    • 11.7.11. Pathtech
    • 11.7.12. Alfa Scientific Designs, Inc.
    • 11.7.13. TCPI, Inc.
    • 11.7.14. Roche
    • 11.7.15. Biophor Diagnostics
    • 11.7.16. Randox Laboratories
    • 11.7.17. Branan Medical
    • 11.7.18. Concateno
    • 11.8. Market Revenue Analysis

12. Vitamin D Diagnostic Testing

  • 12.1. Market Revenue Analysis

13. Renal Dialysis Testing

14. Companion Diagnostics

  • 14.1. Market Revenue Analysis

15. Summary Analysis of the Global IVD High-Growth Market by Geographic Region

  • 15.1. Summary Analysis of the Global IVD Market
  • 15.2. Summary Analysis of the Global IVD High-Growth Market by Geographic Region
  • 15.3. U.S.: Summary Analysis of the IVD High-Growth Market
    • 15.3.1. U.S.: Summary of IVD High-Growth Market
    • 15.3.2. Cardiac Markers
  • 15.4. Europe: Summary Analysis of the IVD High-Growth Market
    • 15.4.1. Summary of IVD High-Growth Market Europe
  • 15.5. Brazil: Summary Analysis of the IVD High-Growth Market
    • 15.5.1. Summary of IVD High-Growth Market Brazil
  • 15.6. Russia: Summary Analysis of the IVD High-Growth Market
    • 15.6.1. Summary of IVD High-Growth Market Russia
  • 15.7. India: Summary Analysis of the IVD High-Growth Market
    • 15.7.1. Summary of IVD High-Growth Market India
  • 15.8. China: Summary Analysis of the IVD High-Growth Market
    • 15.8.1. Summary of IVD High-Growth Market China
  • 15.9. South-East Asia and Japan: Summary Analysis of the IVD High-Growth Market
    • 15.9.1. Japan
    • 15.9.2. South Korea
    • 15.9.3. Rapid Growth Market of IVD HIV/AIDS Testing in Other Asia
    • 15.9.4. Summary of IVD High-Growth Market Other Asia

16. Clinical Laboratory Genomics

  • 16.1. Introduction
  • 16.2. Clinical Laboratory Genomics Testing
  • 16.3. Developments in Clinical Laboratory Genomics
    • 16.3.1. Nucleic Acid Amplification Techniques
    • 16.3.2. Chromosome Imaging
    • 16.3.3. Genomics Technologies
    • 16.3.4. Proteomics Technology
    • 16.3.5. Current Pharmacogenomic Tests
    • 16.3.6. Future Pharmacogenomic Testing

17. Cellular Imaging Cytopathology and Histopathology

  • 17.1. Segment Overview
  • 17.2. The Market
  • 17.3. Market Drivers
  • 17.4. Market Restraints
  • 17.5. Cytology and Histology Technology Platforms
    • 17.5.1. Cytology Screening Procedures and Pap Smear Technology
    • 17.5.2. Histology
    • 17.5.3. Market Drivers
    • 17.5.4. ISH Staining
    • 17.5.5. Special-Stains Staining
  • 17.6. Third-Party Reimbursement
  • 17.7. Competition

18. High-Growth Testing Diagnostic Trends

  • 18.1. Genetic Testing
  • 18.2. Quality Measures
  • 18.3. Moderators of Growth
    • 18.3.1. Diagnostics and the Aging Population
    • 18.3.2. Individualized Medicine
    • 18.3.3. Genetic Testing
  • 18.4. Workforce Issues
  • 18.5. Reimbursement
    • 18.5.1. Cardiovascular
    • 18.5.2. Screening for Diabetes
    • 18.5.3. CPT Test Codes and Payment Amounts
  • 18.6. Rapid Near-Patient Testing in Hospitals
  • 18.7. Satellite Facilities
  • 18.8. Regionalization of Laboratory Care
  • 18.9. Requirements for High-Growth Testing
  • 18.10. Clinical Laboratory Improvement Act (CLIA)

19. Important Technology Trends

20. Molecular Diagnostics a Major Diagnostic Technological Advance

  • 20.1. Polymerase Chain Reaction (PCR)-based Molecular Diagnostics
  • 20.2. Micrarray Technologies and Molecular Diagnostics
  • 20.3. Isothermal Amplification Technologies and Molecular Diagnostics
  • 20.4. Miniaturization Technologies and Molecular Diagnostics (Biochips and Lab on a Chip)

21. Technology Platform Innovations in POCT

  • 21.1. Latest POCT Technological Platforms
    • 21.1.1. Device Miniaturization and Microfluidic Technologies
    • 21.1.2. Minimally-Invasive and Non-Invasive POCT Technologies
    • 21.1.3. Advances in Wireless Technologies
    • 21.1.4. Automation of POCT
    • 21.1.5. Developments in New Genomic Technologies (Genotyping, Haplotyping and Sequencing Technologies)
    • 21.1.6. Advances in Informatics Technologies
    • 21.1.7. Pharmacogenetic Testing
    • 21.1.8. Multi Assay Technologies in POCT
  • 21.2. Developments in Key Technologies
    • 21.2.1. Medical and Biological Sensors and Sensor Systems
    • 21.2.2. Recent Biosensor Product Introductions and Latest Innovative Developments
      • 21.2.2.1. Nanoscale Sensors for the Detection of Cancer Biomarkers
      • 21.2.2.2. ForteBio Introduces Dip and Read Protein G Biosensor for Octet Instruments
      • 21.2.2.3. ForteBio Launches New Octet RED96 System and Dip and Read Protein L Biosensor
      • 21.2.2.4. AgaMatrix Europe Limited Introduces the New Jazz Blood Glucose Meter in the U.K.
      • 21.2.2.5. STMicroelectronics to Manufacture Worlds Smallest Biosensors
      • 21.2.2.6. Universal Biosensors Advances Point of Care Molecular Diagnostic Opportunity
      • 21.2.2.7. Clinitek Advantus-A Semi Automated Urine Analyzer for Point of Care Testing
      • 21.2.2.8. The NOVA 16 STAT Chemistry Analyzer Offers the First All-Electrode-Based Seven Test Chemistry Profile
  • 21.3. Sensor Systems for Diagnostic Applications
  • 21.4. Nanogen (The ELITech Group) Third Generation Point of Care Analyzer
  • 21.5. Philips Development of Magnotech Technology
  • 21.6. Quidel Corporation MChip, AVR Chip and F Chip
  • 21.7. Sanofi-Aventis

22. Data Management and Connectivity

  • 22.1. Wireless LANs
  • 22.2. Connectivity Platforms
    • 22.2.1. DataLink Data Management System
    • 22.2.2. RALS-Plus
      • 22.2.2.1. International Technidyne Corporation HEMOCHRON Signature Elite
      • 22.2.2.2. Siemens Diagnostics Rapidpoint Coag
      • 22.2.2.3. Radiometer
      • 22.2.2.4. HemoCue's DM Hemoglobin
      • 22.2.2.5. Roche Diagnostics
    • 22.2.3. BD.id
    • 22.2.4. Medical Implant Communications Service (MICS)
    • 22.2.5. Conworx Technology
    • 22.2.6. Lab Data Systems
    • 22.2.7. Medasys
    • 22.2.8. NoemaLife
  • 22.3. Advantages of POCT Connectivity
    • 22.3.1. Cost Benefit of POCT and IT Connectivity
    • 22.3.2. Hospital Network Issues
  • 22.4. POCT Analyzer Connectivity Software Solutions
  • 22.5. POCT2-P

23. Biochips for Clinical Applications

  • 23.1. Roche AmpliChip
  • 23.2. Amersham CodeLink
  • 23.3. Breast Cancer DNA Chips
  • 23.4. Osmetech eSensor
  • 23.5. Affymetrix GeneChip System 3000Dx v.2
  • 23.6. Caliper and Cepheid
  • 23.7. Agilent Technologies 2100 Lab-on-a-Chip

24. Company Profiles

  • 24.1. Abaxis, Inc.
  • 24.2. Abbott Laboratories
  • 24.3. Accurex Biomedical Pvt. Ltd.
  • 24.4. Adeza Biomedical Corporation (Hologic)
  • 24.5. Agilent Technologies, Inc.
  • 24.6. Alere, Inc.
  • 24.7. Ambri Ltd.
  • 24.8. American Bio Medica Corporation
  • 24.9. Ani Biotech Oy Ltd.
  • 24.10. Applied Spectral Imaging
  • 24.11. Avitar, Inc.
  • 24.12. Axis-Shield Plc
  • 24.13. Bayer Corporation
  • 24.14. Beckman Coulter (now part of Danaher)
  • 24.15. Becton, Dickinson and Company
  • 24.16. Biomerica, Inc.
  • 24.17. Bio-Rad Laboratories, Inc.
  • 24.18. Calypte Biomedical Corporation
  • 24.19. Chembio Diagnostics, Inc.
  • 24.20. Cozart Bioscience Ltd.
  • 24.21. Denka Seiken Co., Ltd.
  • 24.22. diaDexus, LLC
  • 24.23. Enterix, Inc. (Subsidiary of Quest Diagnostics)
  • 24.24. EY Laboratories, Inc.
  • 24.25. Genetix (Molecular Devices)
  • 24.26. Genzyme Diagnostics
  • 24.27. Hologic Gen Probe
  • 24.28. Instrumentation Laboratory (IL)/Werfen Group
  • 24.29. Jiangnan Biotech
  • 24.30. Johnson & Johnson
  • 24.31. Kyowa Medex Co., Ltd.
  • 24.32. LifeAssays AB
  • 24.33. LifeScan
  • 24.34. Matritech
  • 24.35. A Menarini Diagnostics
  • 24.36. Meretek Diagnostics Group (Otsuka Pharmaceutical, Inc.)
  • 24.37. Meridian Bioscience
  • 24.38. Medix Biochemica
  • 24.39. Myriad Genetics, Inc.
  • 24.40. NOVA Biomedical
  • 24.41. OraSure
  • 24.42. Pheromone Sciences Corporation
  • 24.43. Polymedco, Inc.
  • 24.44. Polymer Technology Systems, Inc.
  • 24.45. QIAGEN N.V.
  • 24.46. Quest Diagnostics, Inc.
  • 24.47. Quidel Corporation
  • 24.48. Radiometer Medical
  • 24.49. Roche Diagnostics
  • 24.50. Shanghai SIIC Kehua Biotech Co., Ltd. (Kehua Biotech)
  • 24.51. Shionogi & Co., Ltd.
  • 24.52. Siemens Healthcare Diagnostics
  • 24.53. Spectral Diagnostics, Inc.
  • 24.54. Trinity Biotech Plc
  • 24.55. Väsamed, Inc.

INDEX OF FIGURES

  • Figure 1.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2012
  • Figure 1.2: Top 13 Country IVD Testing Markets, 2012
  • Figure 1.3: Company Market Share for IVD Testing Markets, 2012
  • Figure 3.1: Geographic Distribution of Chronic HBV Infection
  • Figure 3.2: Evolution of HBV Markers in Acute and Chronic Infection
  • Figure 3.3: U.S. Market Share of HCV Molecular Diagnostic Market, 2012
  • Figure 3.4: Global Market Share (Excluding U.S.) of HCV Molecular Diagnostic Market, 2012
  • Figure 4.1: PCR Analytical Sensitivity Detection Limits
  • Figure 4.2: The Basic Steps of Hybrid Capture 2 Technology
  • Figure 4.3: Diagram of Qiagen QIAsymphony SP/AS instrument
  • Figure 5.1: Global View of HIV Infection, 2009
  • Figure 5.2: Global Trend of HIV Infection, 1991-2011
  • Figure 5.3: Number of People Living with HIV, Newly Infected with HIV and Number of AIDS Deaths in the World, 1990-2011
  • Figure 5.4: Worldwide Rate of New HIV Cases, 1990-2011
  • Figure 5.5: Number of People Receiving Antiretroviral Therapy in Low- and Middle-Income Countries, by Region, 2003-2012 (with Projection)
  • Figure 6.1: U.S. and Outlying Areas Gonorrhea Infection Rates, 1941-2011
  • Figure 6.2: Global Incidence of Malaria
  • Figure 6.3: Mode of Action of Common Malaria RDT Format
  • Figure 6.4: Rate of Tuberculosis (TB) Cases by State/Area in the U.S., 2011
  • Figure 6.5: FIND Pipeline for TB Diagnostics
  • Figure 10.1: Cervical Cancer: 2008 Estimates: World Age-Standardized Incidence Rates per 100,000 Population, Females, World Regions
  • Figure 15.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2012
  • Figure 15.2: Top 13 Country IVD Testing Markets, 2012
  • Figure 15.3: Company Market Share for IVD Testing Markets, 2012
  • Figure 15.4: Indian Diagnostics Market Segments, 2011
  • Figure 15.5: The Chinese Healthcare System
  • Figure 17.1: Worldwide Incidence Rates of Cervical Cancer Per 100,000 Females, 2011
  • Figure 17.2: Cervical Cancer: 2008 Estimates: World Age-Standardized Incidence Rates per 100,000 Population, Females, World Regions

INDEX OF TABLES

  • Table 1.1: Emerging Technology Platforms Driving High-Growth Diagnostics Market Segments
  • Table 1.2: Market Trends in the High-Growth Diagnostics Space
  • Table 1.3: Worldwide Geographic Distribution of Total IVD Testing Market, 2012
  • Table 1.4: Top 13 Country IVD Testing Markets, 2012
  • Table 1.5: Company Market Share for IVD Testing Markets, 2012
  • Table 1.6: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018
  • Table 1.7: Global IVD High-Growth Markets Revenues by Market Segment, 2008-2018
  • Table 1.8: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018
  • Table 1.9: Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
  • Table 3.1: Serological Diagnosis of Hepatitis B Virus Infections
  • Table 3.2: Lower Detection Limits of HBV DNA Assays
  • Table 3.3: Summary of Selected Suppliers of Hepatitis B Virus (HBV) Diagnostic Products by Technology
  • Table 3.4: Global Revenue Forecasts for Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Diagnostic Testing, 2008-2018
  • Table 3.5: Global Revenue Forecasts for Hepatitis B Virus (HBV) Diagnostic Testing, 2008-2018
  • Table 3.6: Efficiency of Available HCV Screening Tests
  • Table 3.7: Recommendations for Diagnostic Testing for Hepatitis C
  • Table 3.8: Hepatitis C Statistics
  • Table 3.9: Novartis Diagnostics Clinical Diagnostic Products Test for the Detection of HCV
  • Table 3.10: Global Revenue Forecasts for Hepatitis C Virus (HCV) Diagnostic Testing, 2008-2018
  • Table 3.11: Major Companies Marketing HCV Molecular Diagnostic Tests: Market Size and Share, 2012
  • Table 4.1: HPV Risk Factors
  • Table 4.2: HPV and Cervical Carcinoma
  • Table 4.3: Key Statistics on Cervical Cancer in the World, 2011
  • Table 4.4: Deaths in Thousands from Cervical Cancer by Region and by Age Group in 2011
  • Table 4.5: Reflex HPV Testing with Cytology
  • Table 4.6: Predictability of HPV Test by Abnormal Pap Smear Type
  • Table 4.7: Qiagen's Digene HC2 High-Risk HPV DNA Test
  • Table 4.8: Commercially Available Molecular Diagnostic Products for HPV Assay
  • Table 4.9: Long-Term Trends in HPV Testing
  • Table 4.10: Global Revenue Forecasts for Human Papillomavirus (HPV) Diagnostic Testing, 2008-2018
  • Table 5.1: Global HIV Statistics, 2011
  • Table 5.2: Antiretroviral Therapy in Low- and Middle-Income Countries by Region, December 2011
  • Table 5.3: Diagnosis of HIV Infection in 2011 for the U.S. and Six Dependent Areas
  • Table 5.4: Estimated Number of AIDS Infection, 2011
  • Table 5.5: Drivers of Demand for HIV Diagnostic Testing
  • Table 5.6: NAT HIV Monitoring Market: Market Drivers Ranked in Order of Impact
  • Table 5.7: Drivers of Demand for HIV Diagnostic Testing
  • Table 5.8: NAT HIV Monitoring Market: Market Restraints Ranked in Order of Impact
  • Table 5.9: Selected POC Infectious Disease Testing Devices, 2011
  • Table 5.10: Commercially Available Molecular Diagnostic Products for HIV Assay
  • Table 5.11: Global Revenue Forecasts for HIV and AIDS Diagnostic Testing, 2008-2018
  • Table 5.12: Competitive Factors Related to HIV Tests
  • Table 6.1: Rapid Strep Tests on the Market
  • Table 6.2: U.S. Chlamydia Infection Rates, 1985-2011
  • Table 6.3: Rapid Tests for Chlamydia
  • Table 6.4: Rapid Tests for Gonorrhea
  • Table 6.5: Commercially-available Rapid Tests for Malaria
  • Table 6.6: Estimated TB Incidence, Prevalence and Mortality, 2011
  • Table 6.7: FIND Partners
  • Table 6.8: Global Market Potential for TB Diagnostic Testing, 2000-2012
  • Table 6.9: MRSA Diagnostics Currently on the Market
  • Table 6.10: Global Revenue Infectious Disease Revenue Analysis, 2008-2018
  • Table 7.1: Medication Chart for Cardiovascular Disease
  • Table 7.2: BNP Clinical Characteristics
  • Table 7.3: Cardiovascular Risk Classification by CRP Level
  • Table 7.4: Clinical Characteristics of D-dimer
  • Table 7.5: Global Revenue Forecasts for Cardiac Marker Testing, 2008-2018
  • Table 8.1: Genetic Testing: Consequences and Challenges
  • Table 8.2: CF Carrier Risk by Ethnic Group
  • Table 8.3: Reasons for CF Testing
  • Table 8.4: CF Gene Detection Rates Vary by Ethnic Background
  • Table 8.5: Global Market for CF Diagnostic Testing, 2008-2018
  • Table 8.6: U.S. Market for CF Diagnostic Testing, 2008-2018
  • Table 8.7: Commercial CF Screening Products
  • Table 8.8: Emerging CF Screening Products
  • Table 9.1: The Fertility Testing Market in the U.S., 2008-2018
  • Table 10.1: Organ-Specific Medicines in Development for Cancer
  • Table 10.2: Estimates for the Leading Sites of New Cancer Cases in the U.S. by Gender, 2013
  • Table 10.3: Estimates for the Leading Sites of Cancer Deaths in the U.S. by Gender, 2013
  • Table 10.4: Worldwide Number of New Cancer Cases and Deaths by Type of Cancer in Men
  • Table 10.5: Worldwide Number of New Cancer Cases and Deaths by Type of Cancer in Women
  • Table 10.6: Estimated Age-Standardized Incidence and Mortality Rates Per 100,000 by World Area, 2008
  • Table 10.7: Worldwide CA 15-3 Sales, 2009-2019
  • Table 10.8: TPA Marker Sensitivity
  • Table 10.9: Worldwide CA 125 Sales, 2009-2019
  • Table 10.10: INFINITI Applications
  • Table 10.11: Global Revenue Forecasts for Cancer Marker Testing, 2008-2018
  • Table 11.1: Drug Testing Needs Tier I for Rapid Serum POCT in the Emergency Department
  • Table 11.2: Stat Urine Testing Drug Recommendations
  • Table 11.3: Selected POC Substance/Drug Abuse Testing Devices, 2011
  • Table 11.4: Selected POC Substance/Drug Abuse Testing Devices, OraSure, 2011
  • Table 11.5: Selected Target Substances and Drugs, 2011
  • Table 11.6: Global Revenue Forecasts for Substance Abuse Testing, 2008-2018
  • Table 12.1: Global Revenue Forecasts for Vitamin D Testing, 2008-2018
  • Table 14.1: Companion Biomarker Market Size, 2008-2018
  • Table 15.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2012
  • Table 15.2: Top 13 Country IVD Testing Markets, 2012
  • Table 15.3: Company Market Share for IVD Testing Markets, 2012
  • Table 15.4: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018
  • Table 15.5: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018
  • Table 15.6: Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
  • Table 15.7: Summary of IVD High-Growth Market U.S., 2011
  • Table 15.8: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing U.S., 2008-2018
  • Table 15.9: U.S. Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
  • Table 15.10: U.S. Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
  • Table 15.11: Specific Cardiac Markers
  • Table 15.12: Cardiac Markers after Onset of Myocardial Infarction
  • Table 15.13: U.S. Cardiac Marker Revenue Forecasts, 2008-2018
  • Table 15.14: Market Share of Cardiac Marker Segment
  • Table 15.15: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Europe, 2008-2018
  • Table 15.16: Europe: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
  • Table 15.17: Europe: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
  • Table 15.18: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Brazil, 2008-2018
  • Table 15.19: Brazil: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
  • Table 15.20: Brazil: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
  • Table 15.21: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Russia, 2008-2018
  • Table 15.22: Russia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
  • Table 15.23: Russia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
  • Table 15.24: Overview of Healthcare in India
  • Table 15.25: Population Projections India, 2000-2020
  • Table 15.26: Statistical Healthcare Data India
  • Table 15.27: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing India, 2008-2018
  • Table 15.28: India: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
  • Table 15.29: India: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
  • Table 15.30: Number of Healthcare Institutions According to Ownership China, 2010
  • Table 15.31: Total Number of Hospitals by Ranking China, 2010
  • Table 15.32: Disease Burden in China: Urban and Rural
  • Table 15.33: China Biotech Reagents Market
  • Table 15.34: Biotechnology Projects Between China and the West
  • Table 15.35: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing China, 2008-2018
  • Table 15.36: China: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
  • Table 15.37: China: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
  • Table 15.38: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Other Asia, 2008-2018
  • Table 15.39: Other Asia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018
  • Table 15.40: Other Asia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018
  • Table 17.1: Medicare National Minimum Payment Amounts for Cervical Pathology Procedures
  • Table 18.1: New CPT Test Codes Introduced in 2008
  • Table 19.1: Employment of Clinical Laboratory Workers, 2006-2016
  • Table 21.1: Common Genotype Techniques
  • Table 22.1: Applications for Wireless LAN Technology
  • Table 22.2: Customized Reports Must Support CAP and JCAHO Requirements
  • Table 22.3: RALS-Plus Point of Care Market Share
  • Table 22.4: Applications of RALS Connectivity with POCT Devices
  • Table 23.1: Biochip Revenues and Growth Rates by Application, 2012 and 2018
  • Table 23.2: Total Biochip Market: Worldwide Revenue Forecasts, 2008-2018
  • Table 23.3: Total Biochip Market: U.S. Revenue Forecasts, 2008-2018
  • Table 24.1: Abaxis, Inc. Financial Figures-Net Sales by Business Sector, 2011-2013
  • Table 24.2: Abaxis, Inc. Financial Figures-Net Sales by Geographic Region, 2011-2013
  • Table 24.3: Abbott Laboratories Financial Figures-Net Sales by Business Sector, 2010-2012
  • Table 24.4: Abbott Laboratories Financial Figures-Net Sales by Geographic Region, 2010-2012
  • Table 24.5: Alere, Inc. Financial Figures-Net Sales by Business Sector, 2008-2012
  • Table 24.6: Alere, Inc. Financial Figures-Net Sales by Geographic Region, 2008-2012
  • Table 24.7: Bayer AG Financial Figures-Net Sales by Business Sector, 2009-2012
  • Table 24.8: Bayer AG Financial Figures-Net Sales by Geographic Region, 2009-2012
  • Table 24.9: Bio-Rad Laboratories, Inc. Financial Figures-Net Sales by Business Sector, 2009-2012
  • Table 24.10: Bio-Rad Laboratories, Inc. Financial Figures-Net Sales by Geographic Region, 2009-2010
  • Table 24.11: Johnson & Johnson Financial Figures-Net Sales by Major Medical and Diagnostics Businesses, 2010-2012
  • Table 24.12: Quidel Product Sales Distribution and Sales, 2010-2012
  • Table 24.13: Danaher Corporation Financial Figures-Net Sales by Business Sector, 2009-2012
  • Table 24.14: Danaher Corporation Financial Figures-Net Sales by Geographic Region, 2010-2012
  • Table 24.15: Roche Group Financial Figures-Net Sales by Business Sector, 2009-2012
  • Table 24.16: Roche Group Financial Figures-Net Sales by Geographic Region, 2010-2012
  • Table 24.17: Roche Group Financial Figures-Net Sales by Sub-Division, 2011 and 2012
Show More
Pricing
Get Notified
Email me when related reports are published